These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 32899797)

  • 1. Biomarkers for Alzheimer's Disease Early Diagnosis.
    Ausó E; Gómez-Vicente V; Esquiva G
    J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimer's Eye.
    Lee S; Jiang K; McIlmoyle B; To E; Xu QA; Hirsch-Reinshagen V; Mackenzie IR; Hsiung GR; Eadie BD; Sarunic MV; Beg MF; Cui JZ; Matsubara JA
    Front Neurosci; 2020; 14():758. PubMed ID: 32848548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Biomarkers for Alzheimer's Disease: From CSF to Blood.
    Zou K; Abdullah M; Michikawa M
    J Pers Med; 2020 Aug; 10(3):. PubMed ID: 32806668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use.
    d'Abramo C; D'Adamio L; Giliberto L
    J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32911755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:
    Sabaei M; Rahimian S; Haj Mohamad Ebrahim Ketabforoush A; Rasoolijazi H; Zamani B; Hajiakhoundi F; Soleimani M; Shahidi G; Faramarzi M
    IBRO Neurosci Rep; 2023 Jun; 14():285-292. PubMed ID: 36942319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.
    van Oostveen WM; de Lange ECM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease.
    Sharma A; Angnes L; Sattarahmady N; Negahdary M; Heli H
    Biosensors (Basel); 2023 Jul; 13(7):. PubMed ID: 37504140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
    Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
    Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular biomarkers of Alzheimer's disease.
    Heaton GR; Davis BM; Turner LA; Cordeiro MF
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):117-25. PubMed ID: 25788142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood.
    Blennow K
    Neurol Ther; 2017 Jul; 6(Suppl 1):15-24. PubMed ID: 28733960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Fluid Biomarkers for Alzheimer's Disease-An Up-To-Date Overview.
    Bălașa AF; Chircov C; Grumezescu AM
    Biomedicines; 2020 Oct; 8(10):. PubMed ID: 33076333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.